ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $105M
Founded date: 2015
Investors 6
| Date | Name | Website |
| 18.07.2020 | Logos Capi... | logoscapit... |
| - | The Longev... | longevity.... |
| - | Foresite C... | foresiteca... |
| - | Lightstone... | lightstone... |
| - | Vivo Capit... | vivocapita... |
| - | HBM Partne... | hbmpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.02.2020 | Series C | $105M | - |
Mentions in press and media 10
| Date | Title | Description |
| 08.08.2024 | ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update | SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, toda... |
| 07.03.2024 | ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | - |
| 05.03.2024 | ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting | - |
| 03.10.2023 | When is a Wall Street disappointment ‘good enough’ for the FDA? | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here. Yesterday’s Nobel wins for Katalin Karikó and Drew Weissman called to mind the ... |
| 01.11.2022 | Betting on CD47 as others ditch the target, ALX borrows up to $100M to push sole clinical drug forward | At its peak, ALX Oncology $ALXO was trading at $88 per share, riding on the promise of blocking CD47, which cancer cells use to broadcast a “don’t eat me” signal. Today, it’s at under $13. The plunge came after two readouts lat... |
| 12.02.2020 | ALX raises $105M for midphase trials of CD47 cancer drug | ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Sponsored by Agilent Technologies How would you like to win fr... |
| 12.02.2020 | ALX raises $105M for midphase trials of CD47 cancer drug | ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence o... |
| 12.02.2020 | ALX Oncology Announces Closing of $105 Million Series C Financing | - |
| 12.02.2020 | ALX Oncology raises $105M in Series C round for checkpoint inhibitor development | The company plans to invest the money in its lead drug candidate, ALX148, a CD47-targeting checkpoint inhibitor that it is developing in combination with other therapies in solid tumors and blood cancers. The drug is designed to maximize th... |
| - | ALX Oncology raises $105M in Series C round for checkpoint inhibitor development | A company developing a drug that targets a protein overexpressed on the surface of cancer cells and enables them to evade the immune system has raised more than $100 million in its latest funding round. Burlingame, California-based ALX Onco... |